Edition:
United Kingdom

Bavarian Nordic A/S (BAVA.CO)

BAVA.CO on Copenhagen Stock Exchange

205.50DKK
15 Jun 2018
Change (% chg)

-- (--)
Prev Close
kr.205.50
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
428,528
52-wk High
kr.444.00
52-wk Low
kr.158.55

Select another date:

Mon, Mar 12 2018

BRIEF-Bavarian Nordic FY EBIT Rises To DKK 353.2‍​ Million

* FY EBIT DKK 353.2‍​ MILLION VERSUS DKK 33.0 MILLION YEAR AGO

BRIEF-Bavarian Nordic Announces Phase 2 Trial Investigating Combination Of Its Immunotherapy CV301 And Nivolumab In Microsatellite Stable Colorectal Cancer

* BAVARIAN NORDIC ANNOUNCES PHASE 2 TRIAL INVESTIGATING COMBINATION OF ITS IMMUNOTHERAPY CV301 AND NIVOLUMAB IN MICROSATELLITE STABLE COLORECTAL CANCER

BRIEF-Bavarian Nordic: Additional Positive Data From Phase 2 Study

* REG-BAVARIAN NORDIC ANNOUNCES ADDITIONAL POSITIVE DATA FROM A PHASE 2 STUDY OF ITS UNIVERSAL RSV VACCINE

BRIEF-Bavarian Nordic: Collaboration to Evaluate CV301 in Combination with durvalumab

* REG-BAVARIAN NORDIC ANNOUNCES COLLABORATION TO EVALUATE CV301 IN COMBINATION WITH DURVALUMAB IN COLORECTAL AND PANCREATIC CANCERS

BRIEF-Bavarian Nordic Announces Positive Results Of Pivotal Phase 3 Study Of Imvamune Smallpox Vaccine

* BAVARIAN NORDIC ANNOUNCES POSITIVE RESULTS OF PIVOTAL PHASE 3 STUDY OF IMVAMUNE® SMALLPOX VACCINE

BRIEF-Bavarian Nordic Announces Planned Departure Of CFO Ole Larsen

* BAVARIAN NORDIC ANNOUNCES THE PLANNED DEPARTURE OF CHIEF FINANCIAL OFFICER, OLE LARSEN

BRIEF-Bavarian Nordic Initiates Clinical Trial With Novel Cancer Immunotherapy

* REG-BAVARIAN NORDIC ANNOUNCES INITIATION OF CLINICAL TRIAL WITH NOVEL CANCER IMMUNOTHERAPY TARGETING BRACHYURY IN CANCER METASTASIS

Merkel's allies, further defying SPD, seek cuts to tax and asylum seeker benefits

BERLIN Germany's Bavarian conservatives are pressing for corporate tax cuts and cuts to welfare payments for asylum seekers, which could complicate talks with the Social Democrats (SPD) on forming a new government.

Select another date: